BIOMAT Database Logo BIOMAT Database Logo

[Clinical evaluation of ursodeoxycholic acid. Glucagon tolerance test in patients with chronic liver disease]. 1988

Y Yamashita, and F Moriyasu, and T Kimura, and S Ono, and T Kawasaki, and T Tamada, and N Ban, and T Nakamura, and H Uchino

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D008111 Liver Function Tests Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions. Function Test, Liver,Function Tests, Liver,Liver Function Test,Test, Liver Function,Tests, Liver Function
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003840 Deoxycholic Acid A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent. Deoxycholate,Desoxycholic Acid,Kybella,Choleic Acid,Deoxycholic Acid, 12beta-Isomer,Deoxycholic Acid, 3beta-Isomer,Deoxycholic Acid, 5alpha-Isomer,Deoxycholic Acid, Disodium Salt,Deoxycholic Acid, Magnesium (2:1) Salt,Deoxycholic Acid, Monoammonium Salt,Deoxycholic Acid, Monopotassium Salt,Deoxycholic Acid, Monosodium Salt,Deoxycholic Acid, Sodium Salt, 12beta-Isomer,Dihydroxycholanoic Acid,Lagodeoxycholic Acid,Sodium Deoxycholate,12beta-Isomer Deoxycholic Acid,3beta-Isomer Deoxycholic Acid,5alpha-Isomer Deoxycholic Acid,Deoxycholate, Sodium,Deoxycholic Acid, 12beta Isomer,Deoxycholic Acid, 3beta Isomer,Deoxycholic Acid, 5alpha Isomer
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001647 Bile Acids and Salts Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones. Bile Acid,Bile Salt,Bile Salts,Bile Acids,Acid, Bile,Acids, Bile,Salt, Bile,Salts, Bile
D014580 Ursodeoxycholic Acid An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic. Deoxyursocholic Acid,3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid,Cholit-Ursan,Cholofalk,Delursan,Destolit,Sodium Ursodeoxycholate,Urdox,Ursacholic Acid,Urso,Urso Heumann,Ursobilane,Ursochol,Ursodiol,Ursofalk,Ursogal,Ursolite,Ursolvan,3 alpha,7 beta Dihydroxy 5 beta cholan 24 oic Acid,Acid, Deoxyursocholic,Acid, Ursacholic,Acid, Ursodeoxycholic,Ursodeoxycholate, Sodium

Related Publications

Y Yamashita, and F Moriyasu, and T Kimura, and S Ono, and T Kawasaki, and T Tamada, and N Ban, and T Nakamura, and H Uchino
Oral ursodeoxycholic acid tolerance test in patients with digestive disease.
January 1981, Gastroenterologia Japonica,
Y Yamashita, and F Moriyasu, and T Kimura, and S Ono, and T Kawasaki, and T Tamada, and N Ban, and T Nakamura, and H Uchino
Ursodeoxycholic acid in chronic liver disease.
September 1991, Gut,
Y Yamashita, and F Moriyasu, and T Kimura, and S Ono, and T Kawasaki, and T Tamada, and N Ban, and T Nakamura, and H Uchino
Treatment of chronic liver disease with ursodeoxycholic acid.
January 1990, The Journal of international medical research,
Y Yamashita, and F Moriyasu, and T Kimura, and S Ono, and T Kawasaki, and T Tamada, and N Ban, and T Nakamura, and H Uchino
Use of ursodeoxycholic acid in patients with liver disease.
February 2002, Current gastroenterology reports,
Y Yamashita, and F Moriyasu, and T Kimura, and S Ono, and T Kawasaki, and T Tamada, and N Ban, and T Nakamura, and H Uchino
Increase of sulfated ursodeoxycholic acid in the serum and urine of patients with chronic liver disease after ursodeoxycholic acid therapy.
April 1996, Journal of gastroenterology and hepatology,
Y Yamashita, and F Moriyasu, and T Kimura, and S Ono, and T Kawasaki, and T Tamada, and N Ban, and T Nakamura, and H Uchino
Ursodeoxycholic acid in the treatment of chronic liver disease.
September 1994, The American journal of gastroenterology,
Y Yamashita, and F Moriyasu, and T Kimura, and S Ono, and T Kawasaki, and T Tamada, and N Ban, and T Nakamura, and H Uchino
Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease.
January 2023, Frontiers in cellular and infection microbiology,
Y Yamashita, and F Moriyasu, and T Kimura, and S Ono, and T Kawasaki, and T Tamada, and N Ban, and T Nakamura, and H Uchino
Ursodeoxycholic acid treatment for chronic cholestatic liver disease.
July 1990, Journal of hepatology,
Y Yamashita, and F Moriyasu, and T Kimura, and S Ono, and T Kawasaki, and T Tamada, and N Ban, and T Nakamura, and H Uchino
Ursodeoxycholic acid oral tolerance test in patients with constitutional hyperbilirubinemias and effect of phenobarbital.
July 1981, Gastroenterology,
Y Yamashita, and F Moriyasu, and T Kimura, and S Ono, and T Kawasaki, and T Tamada, and N Ban, and T Nakamura, and H Uchino
[Clinical evaluation of the glucagon test in fatty liver].
April 1985, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
Copied contents to your clipboard!